Being part of a history-making drug that helps pts with #SCLC live longer and better is the biggest reward a thoracic oncologist could hope for. Grateful being involved and to our pts Just out in @NEJM Presentation today by 1@only @charlesrudin #ASCO25

At the top of the Greek “Grand Canyon” ⛰️ 🌄🥾 #vikos #vikoscanyon #zagori

Post-ESMO weekend-off in beautiful mountain #zagori , history, architecture and nature!!! Because 🇬🇷 is not only about the sea…

Lung Cancer in Nonsmoking Individuals - now out in JAMA 🫁 15-20% of lung cancers 🏭 Risk factors include environmental air pollution (PM2.5) and indoor cooking fumes 🎯Potentially actionable oncogene targets in majority of cases

Phase II study of amivantamab + lazertinib in patients with previously treated #EGFR NSCLC and brain metastases or leptomeningeal disease @JTOonline. In 20 pts with brain metastases, RR 50%, PFS 5.4m, OS 17.4m. With LMD, RR 33%, PFS 7.8m, OS 14.4m. https://t.co/5OPkZdO32M

IBI363 (PD-1/IL-2α-bias), co-development, co-commercialize it in the U.S, commercialization rights outside Greater China and the U.S IBI343 (CLDN18.2 ADC), rights outside China IBI3001 (EGFR/B7H3 ADC), option for the rights outside China https://t.co/ExGD26tKWB

Out on @LungCaJournal 👇 Despite overall poor prognosis, 13% of pts with #NSCLC and PS≥2 reached 5-year OS with IO mono (PD-L1 high setting) Out of ~40 variables, none alone explains it while AI reveals a complex, dynamic prognosis driven by more than disease-related factors

ARTEMIDE-01 #ESMO2025 by @cbcbc1971 TIGIT inhibition is not dead! With the right technology and selection, it seems to be working! Bispecifics really are the way forward in IO? Exciting to see credible signals finally emerging. @myESMO @IASLC #LungCancer #Immunotherapy

Thank you #ESMO25 for the science, the education, the partnerships but most importantly for this human bonding of people who share a common passion to improve cancer care worldwide🌏🌍🌎🏆

🫁 FLAURA2: Exploratory OS analysis. #PasiJanne Survival benefit with osimertinib + platinum-pemetrexed vs monotherapy across poor-prognosis subgroups (CNS mets, L858R, plasma EGFRm, TP53-altered). Reinforces combination as 1L standard for EGFRm NSCLC. @myESMO #ESMO25 #CánCare

#ESMO24 Lung mini orals🔥 4yr update Ph III ALINA trial, adjuvant alectinib in early stage ALK+ NSCLC - 98.4% OS at 4yrs - 90.4% CNS DFS at 4yrs Another prolific result. Questions: 1. who needs chemo pre ALK TKI? 2. Optimising long term tox #ESMO25 #ESMOAmbassadors @myESMO

Zipalertinib in EGFRex20ins NSCLC reported 31% of intracranial ORR 🧠. Today crowded space of TKI for EGFRex20ins. New SoC? Best sequence? Brain activity and toxicity relevant for 1st Line decision. #ESMO25

🔥🚨@OncoAlert Hot Off The Press. Just published @TheLancet in conjunction with presentation @myESMO #ESMO25 Results of: 🎯#HARMONi-6 phase 3 trial of: ⭐️#Ivonescimab + #Chemotherapy VS #Tislelizumab + #Chemotherapy as 1st line Tx for advanced #Squamous non-small-cell

#ESMO25 Lung mini orals🔥 Ph III LungMATE-013 academic trial neoadj chemIO x 4 unresectable IIIB/C NSCLC ➡️surgery v chemo (randomized) - 100pts - 50 randomized sx v RT - pCR 47% - EFS HR favors surgery 0.38 Some disruptive science right here #ESMO25 #ESMOAmbassadors @myESMO

ALEX final OS: - crizo arm dragged down by <50% getting next-gen ALK. Lack of crossover really hurts. - 5-yr OS with alectinib ≈ 5-yr PFS with lorlatinib (CROWN), but only 18% got lorla post alect — we still don’t know the optimal sequence. #ESMO25

Great to see Prof. @perth_meso_dr present results of our international phase 3 #mesothelioma trial #DREAM3R today at #ESMO25 a really enjoyable academic trial collaboration between @TOGAANZ @PrECOGonc

#ESMO25 thoughts on Harmoni-6 data presented in presidential symposium by Dr Shun Lu ➡️ VEGF-targeting Bi-Abs feasible in SqNSCLC ❌ Underrepresention of Women‼️ ➡️ Impressive increase in mPFS, but Tisle not SoC outside China ➡️ potential option for poor prognosis group of

🔥🚨 Hot Off The Press Just published @NEJM In conjunction with presentation @myESMO #ESMO25 Results of #SOHO-02 Phase 1/2 Trial of: ⭐️#Sevabertinib in advanced #HER2 mutant Non-Small Cell #LungCancer. #ORR: ✅71% in treatment naive ✅64% in pre-treated (No prior HER2 Tx)

#ESMO25 Ekegant discussion by @NReguart on the implementation of #tarlatamab in 1L #SCLC focusing on: ✅potential to rescue early progressors ✅ opportunity to offer TCE 1L to pts that would not enter 2L treatment ✅ potential to lift the tail of the OS curve! #some #LCSM

ALEX trial 1st L alectinib (vs crizo) not ⬆️OS but trial not powered for OS. The best drug first? living w/o disease PD and good control of risk of brain PD count most!!Today lorlatinib is one SoC, futute SoC in 1st line Neladalkib (NVL655), ALKZAR trial vs alectinib?. #ESMO25